TALENs targeting HBV: designer endonuclease therapies for viral infections.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

1. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy.Biomarker research · 2024
   Review
2. Gene-Editing and RNA Interference in Treating Hepatitis B: A Review.Viruses · 2023
   Review
3. Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery.Innovation (Cambridge (Mass.)) · 2020
   Review
4. Adenoviral Vectors Armed with PAPILLOMAVIRUs Oncogene Specific CRISPR/Cas9 Kill Human-Papillomavirus-Induced Cervical Cancer Cells.Cancers · 2020
   Article
5. In Vivo Genome Editing as a Therapeutic Approach.International journal of molecular sciences · 2018
   Review
6. Damaging the Integrated HIV Proviral DNA with TALENs.PloS one · 2015
   Article

Corrections and comments

• Comment on
  Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.2013

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as